![J&J says lung cancer drugs Rybrevant and Lazcluze extend survival newsthirst.](https://newsthirst.com/wp-content/uploads/2025/01/106870814-1618920749172-gettyimages-1312652113-47938865-600x400.jpeg)
J&J says lung cancer drugs Rybrevant and Lazcluze extend survival newsthirst.
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically…